Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Total Debt (2016 - 2025)

Historic Total Debt for Abeona Therapeutics (ABEO) over the last 11 years, with Q3 2025 value amounting to $19.8 million.

  • Abeona Therapeutics' Total Debt rose 590.35% to $19.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.8 million, marking a year-over-year increase of 590.35%. This contributed to the annual value of $19.0 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Abeona Therapeutics reported Total Debt of $19.8 million as of Q3 2025, which was up 590.35% from $19.6 million recorded in Q2 2025.
  • In the past 5 years, Abeona Therapeutics' Total Debt registered a high of $34.4 million during Q2 2021, and its lowest value of $4.2 million during Q4 2022.
  • Its 4-year average for Total Debt is $17.9 million, with a median of $18.6 million in 2024.
  • As far as peak fluctuations go, Abeona Therapeutics' Total Debt skyrocketed by 2193.93% in 2021, and later tumbled by 7473.27% in 2022.
  • Over the past 4 years, Abeona Therapeutics' Total Debt (Quarter) stood at $8.4 million in 2021, then tumbled by 50.6% to $4.2 million in 2022, then surged by 355.51% to $19.0 million in 2024, then increased by 4.16% to $19.8 million in 2025.
  • Its last three reported values are $19.8 million in Q3 2025, $19.6 million for Q2 2025, and $19.3 million during Q1 2025.